Analysis of the flavonoid component of bioactive New Zealand mānuka (Leptospermum scoparium) honey and the isolation, characterisation and synthesis of an unusual pyrrole

The flavonoid components of New Zealand mānuka (Leptospermum scoparium) honey have been quantified in a series of 31 honeys of varying non-peroxide antibacterial activity to clarify discrepancies between previous studies reported in the literature. Total flavonoid content was 1.16 mg/100 g honey. The principal flavonoids present were pinobanksin, pinocembrin, luteolin and chrysin and together these represented 61% of the total flavonoid content. 1, 2-formyl-5-(2-methoxyphenyl)-pyrrole, which was weakly correlated with the non-peroxide antibacterial activity, was isolated from the flavonoid fraction and separately synthesised. 1 did not display inhibitory activity against Staphylococcus aureus in vitro and thus the origin of the correlation, which is still unknown, is not a direct contribution.

Kinetics of conversion of dihydroxyacetone to methylglyoxal in New Zealand mānuka honey: Part I--Honey systems

The kinetics of conversion of dihydroxyacetone (DHA) to methylglyoxal (MGO) were investigated in mānuka honeys and DHA-doped clover honeys stored between 4 and 37°C. Both the disappearance of DHA and appearance of MGO were confirmed as overall, first order reactions, albeit probably composites of multiple reactions. Increasing the storage temperature accelerated the rate of DHA loss and the initial rate of formation of MGO, but better conversion efficiency was observed at lower temperature. At 37°C, more MGO was lost at later times in mānuka honey compared to DHA-doped-clover honey. Thirty-seven New Zealand mānuka honeys and four clover honeys were analysed for various chemical and physical properties; comparison of rate constants and these parameters identified some positive correlations.

Quantification of methyl glyoxal in New Zealand Mānuka honey and honey meads

Mānuka honey is New Zealand's (NZ) most globally sought-after honey variety, due to the bioactive effects conferred by methyl glyoxal (MGO). Several NZ meaderies produce Mānuka mead, being a unique NZ product with significant marketing potential; however, it has not been explored in the scientific literature, and MGO has never been quantified in mead of any type. Thus, a versatile HPLC method for the quantification of MGO in both Mānuka mead and honey has been developed, optimised and validated. Two derivatising agents, pentafluorobenzyl hydroxylamine (PFBHA) and o-phenylenediamine were compared, with o-phenylenediamine showing better sensitivity in the mead matrix. To demonstrate the developed method, a survey of the MGO content of commercially available NZ meads was conducted. MGO was detected in four Mānuka meads, with quantifiable levels of 8.20-62.45 mg L-1 present in three samples; however, its presence may be a result of back sweetening with Mānuka honey.

Internal reflectance cell fluorescence measurement combined with multi-way analysis to detect fluorescence signatures of undiluted honeys and a fusion of fluorescence and NIR to enhance predictability

Honey is a complex food matrix that contains diverse polyphenolic compounds. Some phenolics exhibit fluorescence signatures which can be used to evaluate honey quality, and authenticity and to determine botanical origin. Mānuka honey contains two unique fluorescence markers: Leptosperin (MM1) and Lepteridine^TM (MM2) that are derived from Leptospermum scoparium nectar. Fluorescence measurement of supersaturated solutions such as undiluted honeys can be challenged by complex inner filter effects. The current study shows the ability of internal reflectance cell fluorescence measurement and multi-way analysis to detect fluorophores in undiluted honeys. This study scanned honeys from different geographic districts generating excitation emission matrices (250-400/300-600 nm), and by near infrared (NIR) hyperspectral camera (547-1701 nm). PARAFAC and tri-PLS could track two fluorescence markers: MM1 (R² = 0.82 & RMSEP = 138.65) and MM2 (R² = 0.82 & RMSEP = 2.75) from undiluted honey fluorescence data with > 80 % accuracy. Classification of mono-floral, multi-floral and non-mānuka honeys achieved 90 % overall accuracy. Fusion of fluorescence data at ƛ_ex 270 & 330 nm and NIR hyperspectral data combined with multi-block PLS analysis enhances predictability of fluorescence markers further. The study revealed the potential of internal reflectance cell fluorescence measurement combined with chemometrics and data fusion for rapid evaluation of honey quality and botanical origin.

The Leptospermum scoparium (Mānuka)-Specific Nectar and Honey Compound 3,6,7-Trimethyllumazine (LepteridineTM) That Inhibits Matrix Metalloproteinase 9 (MMP-9) Activity

3,6,7-trimethyllumazine (Lepteridine™) is a newly discovered natural pteridine derivative unique to Mānuka (Leptospermum scoparium) nectar and honey, with no previously reported biological activity. Pteridine derivative-based medicines, such as methotrexate, are used to treat auto-immune and inflammatory diseases, and Mānuka honey reportedly possesses anti-inflammatory properties and is used topically as a wound dressing. MMP-9 is a potential candidate protein target as it is upregulated in recalcitrant wounds and intestinal inflammation. Using gelatin zymography, 40 μg/mL LepteridineTM inhibited the gelatinase activities of both pro- (22%, p < 0.0001) and activated (59%, p < 0.01) MMP-9 forms. By comparison, LepteridineTM exerted modest (~10%) inhibition against a chromogenic peptide substrate and no effect against a fluorogenic peptide substrate. These findings suggest that LepteridineTM may not interact within the catalytic domain of MMP-9 and exerts a negligible effect on the active site hydrolysis of small soluble peptide substrates. Instead, the findings implicate fibronectin II domain interactions by LepteridineTM which impair gelatinase activity, possibly through perturbed tethering of MMP-9 to the gelatin matrix. Molecular modelling analyses were equivocal over interactions at the S1' pocket versus the fibronectin II domain, while molecular dynamic calculations indicated rapid exchange kinetics. No significant degradation of synthetic or natural LepteridineTM in Mānuka honey occurred during simulated gastrointestinal digestion. MMP-9 regulates skin and gastrointestinal inflammatory responses and extracellular matrix remodelling. These results potentially implicate LepteridineTM bioactivity in Mānuka honey's reported beneficial effects on wound healing via topical application and anti-inflammatory actions in gastrointestinal disorder models via oral consumption.